Feb 2022 – 35% minority enrollment
Tranquil Clinical Research was the only clinical research unit selected to enroll 200 subjects on a device collection trial and successfully enrolled all 200 subjects (achieving 35% minorities) within 10 business days.
Device Trial Rapid Enrollment
Tranquil Clinical Research successfully recruited and enrolled a difficult interventional device trial within two months; where the sponsor's other sites were unable to enroll in 18 months; becoming the highest enrolling clinical research unit
Study of COVID treatment Quellor has first patient at Louisville hospital
Tranquil is proud to announce the success of our strategic research site partner, the cardiology research team at Jewish Hospital in Louisville, KY! Dr. Naresh Solankhi & his team successfully treated the the first
INmune Bio, Inc. Announces First Patient Dosed in Phase 2 Trial of Quellor™ for Pulmonary Complications in COVID-19 Patients
Congratulations to INmune Bio! Tranquil is proud to be a part of this tremendous effort on enrolling the first patient to this important study. LA JOLLA, Calif, Nov. 09, 2020 (GLOBE NEWSWIRE) -- INmune
Quickest Site Activation
Tranquil Clinical Research was the fastest site activated and quickest site to enroll on a Pivotal COVID clinical trial for a top 20 Pharmaceutical Sponsor.
Remote Study Start-up Whitepaper
Worried about your research program stalling due to Covid-19? Tranquil Clinical Research has the solution for safely and successfully starting up your trial during a pandemic.